Explore the most cutting-edge advancements in modern oncology, including the latest targeted therapies, immunotherapies, and personalised treatments. Discover how groundbreaking research is transforming the cancer landscape, offering new hope and options for patients. We analyse the innovations that are redefining the future of cancer care, from personalised vaccines to CAR-T cell therapy. Stay informed about the newest cancer strategies and the most promising discoveries.
These treatments represent an evolution in immunotherapy, offering greater specificity and fewer side effects. Their continuous development and exploration in early stages of the disease make them crucial in 2026 for various types of tumors.
The combination of immunotherapy with other treatments such as chemotherapy or radiotherapy has been shown to enhance the immune response. This is vital for improving effectiveness in resistant tumors and reducing relapses, even in elderly patients.
CAR-T therapy has revolutionized the treatment of hematological cancers, achieving deep and lasting responses. Its continuous research to expand its application to solid tumors and the creation of in vivo CAR-T cells keep it at the forefront.
These vaccines are designed to stimulate an immune response directed at specific types of cancer, training the immune system to attack existing tumor cells. Personalized mRNA vaccines show robust immunological responses in hard-to-treat tumors.
These drugs are designed to interfere with specific proteins or signaling pathways in cancer cells, offering highly personalized treatments. Their continuous development and the emergence of new drugs in 2025-2026 improve survival and reduce side effects.
All the rankings you can imagine
Thousands of verified votes to discover the best. Your vote here counts
ADCs combine the specificity of a monoclonal antibody with the potency of a chemotherapeutic drug, delivering it directly to the tumor cell. They have demonstrated clear survival benefits and are expanding their use to earlier stages of the disease.
This new generation of biocompatible and biodegradable nanoparticles, developed in January 2026, combines diagnosis and therapy. It allows for the localized destruction of tumors with greater precision, minimizing damage to healthy tissues.
Published in January 2026, this iron nanomaterial leverages the specific conditions of the tumor microenvironment to destroy cancer cells from within. It has completely eliminated tumors in preclinical studies without systemic toxicity, avoiding the side effects of conventional treatments.
Continuous advancements in robotic radiosurgery, with the integration of AI in 2026, allow for the treatment of tumors in challenging locations with greater precision and safety. AI optimizes treatment plans and predicts outcomes, improving efficacy.
These drugs, under development and in use in 2025, allow for highly localized radiation delivery by specifically binding to tumor cells. They minimize damage to healthy tissues, offering targeted and effective therapy.
With fast-track designation by the FDA in February 2026, KB707 represents a novel approach to lung cancer. It uses a modified virus to stimulate the immune system directly in lung cells, aiming to be safer and more effective.
TIL therapy has shown impactful results in 2025-2026, with sustained complete remissions in some patients. It involves expanding the patient's own tumor-infiltrating T-cells and reinfusing them to attack cancer cells, offering significant hope.